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OBJECTIVE: Eosinophilic esophagitis (EoE) can be difficult to diagnose. We aimed to evaluate whether a gene expression score
could differentiate adult EoE cases from non-EoE controls and to determine whether scores normalized after treatment for EoE.
METHODS: We analyzed prospectively collected esophageal biopsies from EoE patients (diagnosed as per consensus guidelines
and after a proton pump inhibitor trial) and non-EoE controls. Gene expression for a previously constructed 94 gene panel was
quantified for a single RNA-later preserved biopsy. For diagnosis, a summary expression score and the area under the receiver
operating characteristic curve (AUC) were calculated. For treatment response (defined aso15 eosinophils per high-power field),
pretreatment and posttreatment EoE samples were compared.
RESULTS: For 91 EoE cases and 174 controls, gene scores for EoE cases were lower than non-EoE controls (mean 198 vs. 420;
Po0.001), with an AUC of 0.927. A score ≤ 263 yielded a positive predictive value= 91%; a score ≥ 349 yielded a negative
predictive value= 90%; only 12% of subjects had an indeterminate score (264–348) by this classification scheme. For the 89 EoE
cases with paired pretreatment and posttreatment samples, overall gene scores improved after treatment from 199 to 343
(Po0.001). This normalization was seen only in cases with histological response (202 vs. 425; Po0.001); scores were unchanged
in non-responders (189 vs. 226; P= 0.25).
CONCLUSIONS: A gene expression score has high diagnostic utility for distinguishing EoE patients from non-EoE controls in
adults and can be used in clinical algorithms. Because it is highly responsive to treatment, the test could be used to monitor
disease status.
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INTRODUCTION
The current paradigm for diagnosing eosinophilic esophagitis
(EoE) requires the presence of symptoms of esophageal
dysfunction, an esophageal biopsy with at least 15 eosinophils
per high-power field (eos/hpf) after a course of a proton pump
inhibitor (PPI), and exclusion of other potential causes of
esophageal eosinophilia.1,2 Although this definition has helped
to provide more consistency in the field,3,4 diagnosis of EoE
remains challenging. Symptoms ofesophageal dysfunction can
be seen in multiple conditions, including gastroesophageal
reflux disease and esophageal motility disorders, and esopha-
geal eosinophilia, even at very high levels, is not specific for
EoE.5,6 Moreover, histological assessment of eosinophilia in
clinical practice is fraught with problems related to tissue
sampling, section thickness, field selection, degranulation, and
even microscope used.3,7 Finally, although endoscopic signs
and biopsy findings can be highly suggestive, there are no
pathognomonic signs of EoE and there is significant clinical
overlap between EoE, gastroesophageal reflux disease, and
other causes of dysphagia.8
Because of these issues, there has been significant
research interest in optimizing the diagnosis of EoE, including
clinical symptom scores,9–12 immunohistochemical staining of
esophageal biopsies,13–17 endoscopic severity scores,18–20
biomarkers,21–24 and gene expression.25–27 Recently,
analysis of the EoE transcriptome identified a panel of 94
differentially expressed genes that held promise for diagnosis
of EoE.28 Genes were selected based on the degree to which
they were upregulated or downregulated, their relation to EoE
pathogenesis, and their involvement in pathways related to
EoE inflammation, and the panel contains pro-inflammatory
genes, epithelial/barrier function genes, and mast cell–related
genes, among others.28,29 The study by Wen et al.28 showed
that a gene expression summary score was highly sensitive
and specific for distinguishing EoE cases from non-EoE
controls, but the score was primarily derived and validated in a
pediatric population, with relatively few adults included in the
study. In addition, although the score appeared to normalize in
EoE cases after successful treatment, assessment of treat-
ment response was not a major focus of that study, and the
1Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina, Chapel Hill,
North Carolina, USA; 2Miraca Life Sciences Research Institute, Irving, Texas, USA; 3Department of Genetics, University of Chapel Hill, Chapel Hill, North Carolina, USA and
4Dallas Veterans Affairs Medical Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Correspondence: Evan S. Dellon, MD, MPH, Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, Department of Medicine,
University of North Carolina, CB#7080, Bioinformatics Building, 130 Mason Farm Road, UNC-CH, Chapel Hill, North Carolina 27599-7080, USA.
E-mail: edellon@med.unc.edu
Received 2 September 2016; accepted 27 Decemeber 2016
Citation: Clinical and Translational Gastroenterology (2017) 8, e74; doi:10.1038/ctg.2017.2
& 2017 the American College of Gastroenterology 2155-384X/17
www.nature.com/ctg
utility of this test has not been validated in an independent
external population.
The aim of this study was to evaluate whether a gene
expression score could accurately differentiate adult EoE
cases from non-EoE controls and to determine whether
scores were affected by treatment for EoE.
METHODS
Study design and patients. This was an analysis of
esophageal biopsies collected during a prospective cohort
study conducted at the University of North Carolina from
2009 through 2015, and details of this study design have
been previously described.12,20,21,30,31 We consecutively
enrolled patients aged 18–80 years who were undergoing
outpatient upper endoscopy for evaluation of symptoms of
esophageal dysfunction such as dysphagia, food impaction,
heartburn, reflux, or chest pain. Patients were enrolled prior
to the endoscopy and before their final diagnosis was
clinically determined. Exclusion criteria were: a known
diagnosis of EoE or a different eosinophilic gastrointestinal
disorder, gastrointestinal bleeding, active anticoagulation,
esophageal cancer, prior esophageal surgery, esophageal
varices, medical instability or multiple comorbidities preclud-
ing enrollment in the clinical opinion of the endoscopist, or
inability to read or understand the consent form. In that parent
study, of the 586 subjects screened, 280 were ineligible
owing to these exclusion criteria.12 Informed consent,
including consent for future use of stored biopsy specimens,
was obtained prior to the endoscopy. This study was
approved by the UNC Institutional Review Board and
registered on clinicaltrials.gov (NCT 01988285).
We used consensus guidelines as the gold standard to
clinically diagnose EoE cases.1,2 Cases were required to have
at least one symptom of esophageal dysfunction, ≥15 eos/hpf
on esophageal biopsy after an 8-week proton pump inhibitor
trial (20–40 mg twice daily of any of the available agents,
prescribed at the discretion of the clinician), and exclusion of
other causes of esophageal eosinophilia. Controls were
subjects who did not meet clinical or histological criteria for
EoE after endoscopy and biopsy. Subjects with proton pump
inhibitor–responsive esophageal eosinophilia were not
included in this study based on prior data that gene expression
profiling could not distinguish them from EoE cases.32 In
addition, we included a set of patients who were “clinically
challenging” from a diagnostic standpoint: they had ≥ 15 eos/
hpf on esophageal biopsy but could not be readily classified as
a case or control based on initial clinical presentation alone.
Data, bio-sample collection, and follow-up. Patient demo-
graphics, symptoms, and endoscopic findings were recorded
prospectively on standardized case report forms. During the
endoscopy, esophageal biopsies were obtained per research
protocol (two from the proximal, one from the middle, and
two from the distal esophagus) for determination of tissue
eosinophil counts and to maximize EoE diagnostic
sensitivity.33,34 We also collected research-protocol gastric
and duodenal biopsies to exclude concomitant eosinophilic
gastroenteritis. Esophageal eosinophil counts were
determined based on our previously validated
methodology.35 The maximum eosinophil density (eos/mm2)
was quantified in five hpfs and then converted to an
eosinophil count (eos/hpf) based on a microscopic field size
of 0.24 mm2, the most commonly reported size in the
literature.3 Slides were masked as to case/control status.
In addition to biopsies obtained for histological assessment,
we also collected additional biopsy samples that were labeled
with a de-identified study number, masked as to case/control
status, and stored at −80 °C RNA-later (Life Technologies/
Thermo-Fisher Scientific, Grand Island, NY) for future use.







Age (mean years± s.d.) 52.1±14.2 37.1±12.7 o0.001
Male (n, %) 73 (42) 54 (59) 0.007
White (n, %) 143 (82) 86 (95) 0.005
Symptoms (n, %)
Dysphagia 120 (69) 89 (98) o0.001
Heartburn 97 (56) 12 (13) o0.001
Abdominal pain 20 (11) 7 (8) 0.33
Nausea/vomiting 11 (6) 1 (1) 0.05
Any atopic disease (n, %) 99 (58) 68 (76) 0.006
Asthma 40 (24) 26 (29) 0.36
Rhinitis/sinusitis 83 (49) 60 (67) 0.006
Dermatitis 11 (7) 7 (8) 0.70
Food allergies 30 (18) 35 (39) o0.001
Endoscopic findings (n, %)
Rings 21 (12) 72 (79) o0.001
Stricture 35 (20) 22 (24) 0.45
Narrowing 6 (3) 32 (35) o0.001
Furrows 12 (7) 79 (87) o0.001
White plaques/exudates 6 (3) 43 (47) o0.001
Edema/decreased
vascularity
5 (3) 52 (57) o0.001
Hiatal hernia 84 (48) 10 (11) o0.001






Eosinophil degranulation 16 (9) 84 (92) o0.001
Eosinophil microabscesses 0 (0) 57 (63) o0.001
Basal layer hyperplasia 18 (10) 39 (73) o0.001
Spongiosis 57 (33) 77 (85) o0.001
Diagnosis (n, %)
EoE — 91 (100) —
GERD 74 (43) — —
Peptic stricture 14 (8) — —
Schatzki’s ring 10 (6) — —
Other stricture 12 (7) — —
Achalasia 5 (3) — —
Esophageal spasm 9 (5) — —
Ineffective esophageal
motility
3 (2) — —
Non-specific dysmotility 9 (5) — —
Functional 34 (19) — —
Normal/no esophageal
pathology
4 (2) — —
EoE, eosinophilic esophagitis; eos/hpf, eosinophils per high-power field; GERD,
gastroesophageal reflux disease.
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This study utilized a single RNA-later-preserved biopsy from
the mid-esophagus (10 cm above the gastroesophageal
junction) for gene expression determination. The decision to
use a single mid-esophageal biopsy was based on our prior
work showing that gene expression in EoE and controls was
similar throughout the esophagus.31
Patients diagnosed with EoE were treated as clinically
indicated by their gastroenterologist. They could receive
treatment with topical corticosteroids (either oval viscous
budesonide 1 mg twice daily or fluticasone from a multi-dose
inhaler, 880 mcg twice daily) for 8 weeks36–38 or dietary
therapy with the six-food elimination diet for 6 weeks39,40
based on personal preference. When the initial course of
therapy was completed, patients had a repeat upper endo-
scopy with biopsy during which time a repeat set of
esophageal biopsies was obtained using identical protocols
as the baseline endoscopy.
Gene expression determination. After patient enrollment
was complete, the mid-esophageal biopsies in RNA-later
were removed from − 80 °C storage and sent on dry ice for
processing at Miraca Life Sciences (Phoenix, AZ) for gene
expression testing. The supernatant was removed after
thawing and the tissue was homogenized. RNA extraction
was performed on the homogenized specimens using the
RNeasy Mini Extraction Kit (Qiagen, Valencia, CA) per the
manufacturer’s instructions, and the concentration was
measured using spectrophotometry (NanoDrop, Wilmington,
DE). A concentration of 16.5 ng/μl of RNA for a total of 500 ng
was considered acceptable. cDNA synthesis was carried out
using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA)
with PCR performed on ABI 9700 (Applied Biosystems,
Foster City, CA). The cDNA and TaqMan Universal Master
Mix II, no UNG (Life Technologies) were loaded onto custom
Taqman TLDA cards containing preloaded Taqman gene
expression assays in a 384-well format. This consisted of the
94 gene panel that was previously developed for EoE28 and 2
housekeeping genes (GAPDH and 18S) (EoGenius, Miraca
Life Sciences, Irving, TX). PCR was performed on Quant
Studio 7 (Life Technologies) to determine the gene expres-
sion levels measured as threshold cycles (Ct). Samples with
a GAPDH value of o30 Ct were considered acceptable for
analysis.
Using this expression data, a summary score was calcu-
lated using a previously established algorithm.28 Specifically,
the Ct value of the housekeeping gene was subtracted from
the Ct value of each gene of interest to acquire the ΔCT, and
then the absolute values of the normalized gene Ct values
were summed for each gene in the gene expression panel.
Statistical analysis. We summarized clinical features of the
study populations with descriptive statistics. Baseline data for
cases and controls, including the mean gene scores, were
compared using two-sample t-tests for continuous variables
and chi-square for categorical variables. We assessed the
gene score cut point (o333 vs. ≥333) that was previously
found to maximize diagnostic accuracy (a score o333 was
shown to be characteristic of EoE)28 evaluated the correlation
between the maximum eosinophil counts and the gene
scores and performed additional receiver operator character-
istic curve analyses to calculate the area under the curve
(AUC) and operating characteristics for our data set. With
these data, we explored gene score ranges, rather than a
single cut point, that would optimize both positive and
negative predictive values (PPV and NPV, respectively) while
minimizing indeterminate results. Next we analyzed the
baseline and posttreatment gene scores for EoE cases using
paired t-tests. The posttreatment gene scores were also
stratified by histological response status, defined as 15
eos/hpf.41 Finally, we examined the gene scores for clinically
challenging patients (≥15 eos/hpf on esophageal biopsy but
with an indeterminate initial clinical presentation). For these
cases, the gold standard was the final clinical diagnosis
based on all available testing, treatment, and follow-up data in
the medical record. Analyses were performed with Stata 9.2
(StataCorp, College Station, TX).
RESULTS
Patient characteristics. A total of 174 non-EoE controls and
91 incident EoE cases had samples analyzed in this study.
Compared with controls, EoE cases were younger (37 vs. 52
Table 2 Baseline and follow-up gene scores
Non-EoE controls (n=171) EoE cases (n=90) Pa
Gene score (mean± s.d.)
Baseline 419.7±66.1 197.8±138.4 o0.001
Posttreatmentb 342.5±138.1
Pa o0.001








EoE, eosinophilic esophagitis; eos/hpf, eosinophils per high-power field.
aCases and controls compared with a two-sample t-test; cases before and after treatment compared with a paired t-test.
bn= 89 EoE cases with posttreatment samples.
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years; Po0.001), more frequently male (59% vs. 42%;
P=0.007) and white (95% vs. 82%; P= 0.005), and had
more atopic diseases (76% vs. 58%; P= 0.006) (Table 1).
Cases also more commonly had endoscopic findings of
esophageal rings, narrowing, linear furrows, white plaques/
exudates, and edema/decreased vascularity. The baseline
maximum eosinophil counts were 135.9±123.4 in the EoE
cases and 1.5±3.3 in the controls (Po0.001) (Table 1).
Baseline gene expression scores. Sufficient RNA was
available for 171 controls and 90 cases. At baseline, the
mean gene expression score was significantly lower in
EoE cases compared with controls (197.8±138.4 vs.
419.7± 66.1; Po0.001) (Table 2). The heat map showing
gene expression for the gene panel used for all subjects is
presented in Figure 1. The maximum eosinophil count
inversely correlated with the gene score (Pearson’s
R=−0.65; Po0.001). On receiver operator characteristic
analysis, the AUC was 0.927 for diagnosis of EoE (Figure 2).
The gene score cut point of 333 correctly classified 72 of the
cases (79%) and 158 of the controls (91%), corresponding to
a κ of 0.71. After optimizing potential gene score ranges, we
found that a score ≤263 yielded a PPV=91%, a score ≥349
yielded an NPV= 90%, and only 12% of subjects had an
indeterminate score (range: 264–348) by this classification
scheme (Table 3).
Posttreatment gene expression scores. There were 89
EoE cases with paired pretreatment and posttreatment
samples. A total of 81 (91%) were treated with topical
steroids, 75 of whom (93%) were prescribed a budesonide
slurry at 2 mg/day, and 6 of whom were prescribed
Figure 1 Gene expression heat map for controls (gray bar) and eosinophilic esophagitis (EoE) cases (black back). Yellow indicates more highly expressed genes and blue
indicates less highly expressed genes.
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fluticasone in a multi-dose inhaler at 1760 mcg/day; the
remaining patients were treated with dietary elimination. The
overall gene scores after treatment increased to
342.5±138.1 (Po0.001) (Table 2). The heat map showing
pretreatment and posttreatment gene expression for EoE
cases is presented in Figure 3. Of note, this increase was
seen only in those cases with histological response
(201.5±137.0 vs. 425.3±50.1; Po0.001); scores were
unchanged in histological non-responders (189.1± 142.8
vs. 226.4± 142.1; P=0.25; Figure 4).
Utility of gene expression scores in clinically challenging
patients. There were 15 patients (mean age 53 years; 80%
male) who had elevated eosinophil counts and clinically
indeterminate features on their baseline endoscopy and
biopsy (Supplementary Table S1). The mean peak eosinophil
count in this group was 55 eos/hpf, and the mean baseline
gene score was 313, in the indeterminate range by the
classification scheme above. After all clinical features and
subsequent testing were considered, only one patient was felt
clinically to have overlapping EoE and gastroesophageal reflux
disease; the gene score for this patient was 231, in the range
suggestive of EoE. Ten patients (67%) had gene scores ≥264,
putting them in either the indeterminate or non-EoE range,
despite their elevated esophageal eosinophil count. None of
these patients were clinically diagnosed with EoE.
DISCUSSION
Because the clinical, endoscopic, and histological features of
EoE are non-specific, the diagnosis of EoE remains challen-
ging. The description of a characteristic gene expression
pattern in EoE patients, the EoE transcriptome,25,26 was the
foundation for the eventual development of a molecular
strategy for diagnosis of EoE. A summary score based on a
panel of 94 genes with differential expression in EoE
compared with non-EoE controls showed great promise for
diagnosis of EoE.28 Our study focused on the clinical utility of
this gene expression summary score in adults and several
results were notable. First, the score discriminated EoE cases
from non-EoE controls with a high degree of accuracy, though
not perfectly. Second, we were able to adapt a scoring system
to provide clinically relevant probabilistic score ranges, rather
than a single dichotomous threshold for diagnosis. Third, we
showed that a positive gene score reliably normalizes after
histological treatment response, suggesting that it may be
used to assess treatment response in place of a set of biopsies
obtained for histological analysis. Finally, there appeared to be
some utility in applying the gene score to cases that were
clinically indeterminate.
There have been several studies that have examined gene
expression in EoE, showing differences in individual genes or
microRNAs between EoE cases and controls and that these
individual markers could normalize with treatment.25–28,42–45
However, the landmark paper by Wen et al.28 was the first to
develop an overall gene score and then to go further by
validating its use for EoE diagnosis. Although the score was
primarily evaluated in a pediatric population with relatively few
adults included, and while treatment response was not the
main focus, the performance of this summary score was
impressive. A cutoff of 333 perfectly distinguished EoE cases
from non-EoE controls in the initial study phase (AUC=1.00)
and was nearly perfect in the follow-up validation phase
(AUC=0.97). Our results also showed an outstanding AUC
(0.93). The main difference was that the threshold of 333,
though good, was not perfect (κ=0.71) and some patients
were misclassified. This discrepancy may be explained by
methodology. Because this is the first large-scale external
validation of the gene expression panel, it is not surprising that
a cut point developed in a different population does not have
identical performance characteristics. In addition, the prior
study processed samples individually in a research laboratory,
while the present study utilized amore automated process that
could be used in the clinical setting. To address this, we
defined ranges, based on the clinical probability of EoE, that
maximized PPV and NPV and minimized indeterminate
results. In addition, the test had promise in cases that had
high levels of eosinophilia on biopsy but had a clinically
indeterminate presentation, something that no study to date
has examined.
In addition to the test’s diagnostic utility, we were able to
show that it might have an even stronger role in monitoring of
therapy. Currently, there are few studies that systematically
assess or define the “best” histologicalal threshold in EoE,41
clinical trials have substantial heterogeneity in the end points
that have been used,5,46 and guidelines do not recommend a
specific cut point to monitor response.2 In practice, multiple
biopsies are obtained from multiple locations throughout the
esophagus, and the posttreatment peak eosinophil count is
determined from review of these samples. Because eosino-
philia is patchy,34,47 there could be sampling error during this
evaluation. In contrast, it appears that gene expressionmay be
more consistent throughout the esophagus,31 and our results
demonstrate that a single biopsy from a patient who had
histological response also had normalization of a gene
expression. It is therefore intriguing to speculate whether
gene expression normalization might provide a more efficient
and accurate way to define tissue response to treatment in
Figure 2 Receiver operator characteristic curve showing the utility of the gene
expression panel for diagnosis of eosinophilic esophagitis. AUC, area under the
receiver operating characteristic curve.
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EoE. However, future studies will need to assess other mea-
sures of response (symptoms, endoscopic findings, histological
findings besides eosinophil count alone) to fully explore the
use of this gene panel as a treatment outcome measure.
Additionally, even with the data presented here, the role and
availability of this test in clinical diagnostic and treatment
monitoring algorithms must still be defined. As of now, there
may not be a need for use in clear-cut cases, but because
diagnostic features of EoE are not specific, the test may have
the most value in settings of clinical uncertainty or when a
baseline value is needed for subsequent treatment monitoring.
This paper has some limitations to acknowledge. This study
was conducted in adults at a single tertiary care referral center,
so it is possible that results are not generalizable. However,
the study design enrolled all patients undergoing endoscopy
for symptoms of esophageal dysfunction, a population that
is likely to be similar to that in many other endoscopic
suites. In addition, the biopsy samples that we used were
preserved in RNA-later. Were a gene panel to be employed in
clinical practice, formalin-fixed paraffin-embedded (FFPE)
samples would most likely be used. The same gene expression
Figure 3 Gene expression heat map for cases before (orange bar) and after (purple bar) treatment. Yellow indicates more highly expressed genes and blue indicates less
highly expressed genes.








0.70–1.0 Likely ≤263 PPV 91%
0.30–0.69 Indeterminate 264–348 12%of samples
in this range
0–0.29 Unlikely ≥349 NPV 90%
EoE, eosinophilic esophagitis; NPV, negative predictive value; PPV, positive
predictive value.
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panel has been shown to have good discriminative ability in
FFPE samples, but we did not perform external validation, and
this additional validation as well as confirmation of the proposed
score ranges from this paper must still be explored for RNA
derived from FFPE. Moreover, external validation of the cut
points proposed in this study would also be required at different
centers and in different populations. Although we included a
patient population with high eosinophil counts and clinically
indeterminate presentations, the clinical care and follow-up
testing of these patients were not standardized, so those results
should be interpreted with caution. The indeterminate patients
also represented a relatively small sample, and in a number of
cases a careful clinical evaluation could yield a correct diagnosis
without using a gene expression test. In addition, our study
cannot address the issue of whether gene expression can
replace standard histological analysis in EoE diagnostic algo-
rithms, and future research will need to elucidate the best way to
utilize a test that could “rule in EoE”, in contrast to an eosinophil
count that is non-specific. The strengths of the study include the
rigorous prospective design, meticulous sample handling that
was identical for all subjects, and obtaining samples before case/
control status was assigned. Moreover, this large case/control
populationwas independent from the population used to develop
and initially validate the test, the laboratory wasmasked to case/
control statuswhen gene scores were determined, and samples
were processed and run with the same set of equipment that
would be used in a clinical setting.
In conclusion, this prospective cohort study showed that a
gene expression profile run on a single esophageal biopsy had
an excellent ability to discriminate EoE cases from non-EoE
controls, and we were able to generate probabilistic score
ranges with high PPV and NPVs while minimizing samples
with intermediate scores. In addition, patients with marked
esophageal eosinophilia but with an indeterminate initial
clinical presentation were able to be categorized as unlikely
to have EoE based on higher gene scores. Although this test
could be used in clinical algorithms, its exact place in
these algorithms and utility above standard histological
analysis for diagnosis is still exploratory and yet to be
determined. Finally, because the gene scores were respon-
sive to treatment and normalized in patients who also had
histological response, it is possible that in the future a single
esophageal biopsy posttreatment could be used to define
tissue response in EoE.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Diagnosis of eosinophilic esophagitis (EoE) remains
challenging as the clinical signs and biopsy findings are not
specific.
✓ A gene expression panel for diagnosis of EoE has recently
been developed, but its utility in adults and role for
monitoring treatment response have not been extensively
evaluated.
WHAT IS NEW HERE
✓ This large cohort study of adults with EoE and non-EoE
controls analyzed a gene expression panel in prospectively
collected esophageal biopsies and summary scores were
calculated.
✓ Gene scores were markedly lower in newly diagnosed EoE
cases compared with controls, with a very high diagnostic
utility (area under the receiver operating characteristic
curve was 0.927).
✓ A probabilistic range of gene scores was generated to
divide patients suspected of EoE into being highly likely to
have it, unlikely to have it, and indeterminate.
✓ Gene scores were highly responsive to treatment, with
normalization of gene expression in EoE patients who were
histological responders but not in non-responders. This
suggests that the test could be used to monitor disease
status.
Figure 4 Mean gene expression scores (± s.d.) in controls (green bar) and
eosinophilic esophagitis (EoE) cases (dark blue bar) at baseline, in all EoE cases
after treatment, and in EoE cases after treatment stratified by histological response
status (responders defined aso15 eosinophils per high-power field).
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